Drug · DIN 02470489
BENLYSTA
SINGLE DOSE AUTO-INJECTOR
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since May 14, 2018; first marketed May 14, 2018.
- Drug Identification Number (DIN)
- 02470489
- Company (DIN owner)
- Glaxosmithkline IncMississauga, Ontario, Canada
- Schedule
- Prescription; Schedule d
- Dosage form
- Solution
- Route
- Subcutaneous
- Therapeutic class (ATC)
- Belimumab L04AG04
- Class
- Human
- Record last updated
- August 6, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| BELIMUMAB | 200 MG | 1 ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- December 7, 2017: NOC 20127Supplement to a New Drug Submission (SNDS) · New formulation and route of administration
Other DINs named BENLYSTA
- DIN 02370050 · Marketed
- DIN 02370069 · Marketed
- DIN 02470470 · Cancelled Pre Market